Multi-Faceted Mass Spectrometric Investigation of Neuropeptides in Callinectes sapidus
May 31st, 2022
Mass spectrometric characterization of neuropeptides provides sequence, quantitation, and localization information. This optimized workflow is not only useful for neuropeptide studies, but also other endogenous peptides. The protocols provided here describe sample preparation, MS acquisition, MS analysis, and database generation of neuropeptides using LC-ESI-MS, MALDI-MS spotting, and MALDI-MS imaging.
Overview
This article presents a mass spectrometric approach for the characterization of neuropeptides, detailing methods for sequence, quantitation, and localization. The protocols outlined are applicable not only to neuropeptides but also to other endogenous peptides.
Key Study Components
Area of Science
- Neuroscience
- Mass Spectrometry
- Peptide Analysis
Background
- Endogenous peptides are often under-examined despite their biological significance.
- Mass spectrometry offers high sensitivity for detecting neuropeptides.
- Understanding neuropeptide expression can aid in therapeutic development.
- Protocols for neuropeptide extraction and analysis are essential for advancing research.
Purpose of Study
- To provide a comprehensive workflow for neuropeptide analysis.
- To facilitate the quantitation and localization of neuropeptides.
- To support the discovery of neuropeptide biomarkers for diseases.
Methods Used
- Sample preparation using acidified methanol for neuropeptide extraction.
- Mass spectrometry acquisition techniques including LC-ESI-MS and MALDI-MS.
- MS analysis for quantification and localization of neuropeptides.
- Database generation for neuropeptide identification.
Main Results
- Successful extraction and analysis of neuropeptides from crustacean brain tissue.
- Demonstration of mass spectrometry's capability to target specific neuropeptides.
- Identification of neuropeptide expression patterns relevant to disease.
- Establishment of protocols that can be adapted for various endogenous peptides.
Conclusions
- The optimized workflow enhances neuropeptide research capabilities.
- Mass spectrometry is a valuable tool for neuropeptide studies.
- Future applications may lead to novel peptide therapeutics and biomarkers.
Frequently Asked Questions
Executive Industry Relevance
Neuropeptide characterization remains a bottleneck in target validation due to low abundance and high chemical diversity, limiting mechanistic de-risking in early discovery. Mass spectrometry enables unbiased detection and quantification of endogenous peptides, supporting biomarker discovery and therapeutic hypothesis testing. This workflow provides a scalable, reproducible platform for neuropeptide profiling that can be adapted across species and peptide classes, enhancing predictive confidence in target selection.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of therapeutic hypotheses by identifying endogenous neuropeptides involved in physiological pathways.
- Operational Value: Supports functional target validation through detection of bioactive peptides at physiologically relevant concentrations.
- Predictive Value: Facilitates portfolio triage by providing quantitative expression data to prioritize targets with disease relevance.
Screening & Assay Development
- Scientific Value: Generates validated neuropeptide reference databases for use in targeted and untargeted screening assays.
- Operational Value: Standardizes sample preparation and desalting procedures to improve reproducibility across LC-MS and MALDI-MS platforms.
- Scalability: Enables multiplexed detection of multiple neuropeptides in a single run, increasing throughput for screening campaigns.
Translational & Preclinical Research
- Scientific Value: Links neuropeptide expression patterns to disease-related phenotypes through localization and quantitation data.
- Operational Value: Provides antibody-free localization via MALDI-MS imaging, reducing dependency on immunoreagents.
- Translational Continuity: Supports biomarker validation by enabling detection of neuropeptides in complex tissues without prior sequence knowledge.
Pipeline & Workflow Integration
The method integrates into early discovery for target identification, proceeds through assay development for screening readiness, and supports translational research for biomarker validation, creating a continuous workflow from hypothesis to preclinical evaluation.
- Discovery Biology: Enables hypothesis testing by detecting endogenous neuropeptides that modulate signaling pathways relevant to disease models.
- Screening: Delivers quantitative, reproducible peptide profiles suitable for assay standardization and hit confirmation in screening cascades.
- Analytics: Provides label-free quantification and localization readouts that allow comparison of neuropeptide levels across experimental conditions.
- Translational Research: Connects discovery-phase neuropeptide identification to preclinical validation through spatial and temporal expression mapping.
- Enterprise Reuse: Establishes a adaptable platform for endogenous peptide analysis that can be applied across multiple projects and disease areas.
Operational & Enterprise Impact
- Scientific Value: Increases target validation confidence by reducing mechanistic ambiguity in neuropeptide signaling pathways.
- Operational Value: Enhances reproducibility through standardized extraction, desalting, and MS acquisition protocols.
- Strategic Value: Improves go/no-go decisions by providing early-stage biomarker and target expression data.
- Portfolio Impact: Enables risk-adjusted prioritization of targets based on quantitative neuropeptide data from disease-relevant systems.
Implementation Considerations
- Requires expertise in mass spectrometry, sample preparation, and peptide data analysis.
- Depends on access to LC-MS and MALDI-MS instrumentation with appropriate sensitivity for low-abundance peptides.
- Necessitates standardization of extraction and desalting protocols across laboratories for cross-site reproducibility.
- Involves adaptation of database search parameters for species with limited genomic resources, such as invertebrates.
- Limited by the endogenous abundance of neuropeptides, requiring optimized enrichment for low-copy-number species.
Biopharma FAQs
Chapters in this video
0:04
Introduction
0:49
LC-ESI-MS Analysis of Neuropeptides
2:45
MALDI-MS Spotting Analysis of Neuropeptides
4:13
MALDI-MS Imaging Analysis of Neuropeptides
5:36
Discovering Novel Putative Neuropeptides Using De Novo Sequencing and Transcriptome Mining for Predicted Neuropeptide Sequences
6:57
Results: De Novo Sequencing and MALDI-MS Imaging of Neuropeptides
8:41
Conclusion
